Antiretroviral activity and pharmacokinetics in mice of oral bis(pivaloyloxymethyl)-9-(2-phosphonylmethoxyethyl)adenine, the bis(pivaloyloxymethyl) ester prodrug of 9-(2-phosphonylmethoxyethyl)adenine

Antimicrob Agents Chemother. 1996 Jan;40(1):22-8. doi: 10.1128/AAC.40.1.22.

Abstract

Lipophilic ester prodrugs of 9-(2-phosphonylmethoxyethyl)adenine (PMEA), i.e., bis(pivaloyloxymethyl)-PMEA [bis(POM)-PMEA] and diphenyl-PMEA, have been synthesized in an attempt to increase the oral bioavailability of this broad-spectrum antiviral agent. The antiretroviral efficacy was determined in severe combined immune deficiency (SCID) mice infected with Moloney murine sarcoma virus (MSV). They were treated twice daily for 5 days after infection. Oral treatment with bis(POM)-PMEA at a dose equivalent to 100 or 50 mg of PMEA per kg of body weight per day proved markedly effective in delaying MSV-induced tumor formation and death of the mice. Oral bis(POM)-PMEA afforded anti-MSV efficacy equal to that of subcutaneous PMEA given at equimolar doses. Oral treatment with PMEA or diphenyl-PMEA proved less efficient. Similarly, in mice infected with Friend leukemia virus (FLV), oral treatment with bis(POM)-PMEA at a dose equivalent to 100 or 50 mg of PMEA per kg per day effected a marked inhibition of FLV-induced splenomegaly (87 and 48% inhibition, respectively), the efficacy being equal to that of PMEA given subcutaneously at equivalent doses. Pharmacokinetic experiments with mice showed that the oral bioavailabilities of PMEA following oral gavage of bis(POM)-PMEA, diphenyl-PMEA, or PMEA (at a dose equivalent to 50 mg of PMEA per kg) were 53,3, and 16%, respectively. These data were calculated from the levels of free PMEA in plasma. Also, the recoveries of free PMEA in the urine upon oral administration of bis(POM)-PMEA, diphenyl-PMEA, or PMEA (at a dose equivalent to 25 mg of PMEA per kg) were 48, 4, and 7%, respectively. Oral bis(POM)-PMEA was not recovered from plasma, suggesting that it was readily cleaved to free PMEA. In contrast, diphenyl-PMEA was not efficiently cleaved to free PMEA, resulting in a rather low oral bioavailability of PMEA from this prodrug. Bis(POM)-PMEA appears to be an efficient oral prodrug of PMEA that deserves further clinical evaluation in human immunodeficiency virus-infected individuals.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenine / analogs & derivatives*
  • Adenine / pharmacokinetics
  • Adenine / pharmacology
  • Animals
  • Anti-HIV Agents / pharmacokinetics
  • Anti-HIV Agents / pharmacology
  • Antiviral Agents / pharmacokinetics*
  • Antiviral Agents / pharmacology*
  • Female
  • Friend murine leukemia virus / drug effects
  • Humans
  • In Vitro Techniques
  • Leukemia, Experimental / drug therapy
  • Leukemia, Experimental / virology
  • Mice
  • Mice, Inbred Strains
  • Mice, SCID
  • Moloney murine sarcoma virus / drug effects
  • Organophosphonates*
  • Prodrugs / pharmacokinetics*
  • Prodrugs / pharmacology*
  • Rats
  • Retroviridae / drug effects*
  • Retroviridae Infections / drug therapy
  • Retroviridae Infections / virology
  • Sarcoma, Experimental / drug therapy
  • Sarcoma, Experimental / prevention & control
  • Tumor Virus Infections / drug therapy

Substances

  • Anti-HIV Agents
  • Antiviral Agents
  • Organophosphonates
  • Prodrugs
  • bis(pivaloyloxymethyl)-9-(2-phosphonylmethoxyethyl)adenine
  • diphenyl-9-(2-phosphonylmethoxyethyl)adenine
  • adefovir
  • Adenine